Baseline Tumor Burden Assessed With AI‐Guided PET/CT Total Metabolic Tumor Volume (TMTV) and LDH Levels Predict Efficacy of CAR‐T in Aggressive B‐Cell Lymphoma
Hematological Oncology · 2025-01 · 43 (1)
DOI: 10.1002/hon.70029 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematological Oncology, online erschienen am 23.12.2024. Verfasst von Eugenio Galli und 10 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Scienze di Laboratorio Ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Tumor Burden, L-Lactate Dehydrogenase. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Disease burden is a critical determinant of outcomes in CAR‐T therapy for B‐cell lymphomas, and one of the most widely used techniques for its assessment is Total Metabolic Tumor Volume (TMTV) measured via [ 18 F]FDG PET/CT. Biological parameters may further refine the risk profile. We analyzed baseline [ 18 F]FDG PET/CT scans from 40 patients treated with CAR‐T, using an AI‐based automated segmentation algorithm to determine TMTV. Our analysis identified that a baseline TMTV greater than 48.4 cm³ and elevated LDH independently predicted progression‐free survival (PFS) after CAR‐T therapy (HR 4.28, p = 0.007, and HR 8.20, p < 0.001, respectively). We then proposed a 0‐to‐2 risk score, assigning one point each for elevated TMTV and elevated LDH. All patients with a score of two experienced a PFS of less than 90 days following CAR‐T infusion. Among the remaining patients, those with 0 points versus 1 point demonstrated a 3‐month PFS of 100% versus 85%, a 6‐month PFS of 92% versus 53%, and a 12‐month PFS of 83% versus 53%, respectively. Importantly, patients with high baseline TMTV who achieved a TMTV reduction to less than 1.99 cm³ by day 30 had a PFS of 66%, significantly better compared to those who did not achieve this reduction. AI‐guided TMTV assessment, combined with LDH levels, provides a rapid and sensitive method for risk stratification at the bedside, which could help optimize patient management prior to CAR‐T therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dipartimento di Scienze di Laboratorio Ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
- Unità di Medicina Nucleare, Dipartimento di Diagnostica per Immagini e Radioterapia Oncologica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
- Sezione di Ematologia, Università Cattolica Del Sacro Cuore, Rome, Italy.
- Sezione di Medicina Nucleare, Università Cattolica Del Sacro Cuore, Rome, Italy.
ORCID-Profile: Federica Sorà
Zitieren
APA
Galli, E., Guarneri, A., Sorà, F., Viscovo, M., Pansini, I., Maiolo, E., Alma, E., Annunziata, S., Sica, S., Leccisotti, L., & Hohaus, S. (2025). Baseline Tumor Burden Assessed With AI‐Guided PET/CT Total Metabolic Tumor Volume (TMTV) and LDH Levels Predict Efficacy of CAR‐T in Aggressive B‐Cell Lymphoma. Hematological Oncology, 43(1). https://doi.org/10.1002/hon.70029
Vancouver
Galli E, Guarneri A, Sorà F, Viscovo M, Pansini I, Maiolo E, et al. Baseline Tumor Burden Assessed With AI‐Guided PET/CT Total Metabolic Tumor Volume (TMTV) and LDH Levels Predict Efficacy of CAR‐T in Aggressive B‐Cell Lymphoma. Hematological Oncology. 2025;43(1). doi:10.1002/hon.70029
BibTeX
@article{Galli2025,
author = {Galli, Eugenio and Guarneri, Andrea and Sorà, Federica and Viscovo, Marcello and Pansini, Ilaria and Maiolo, Elena and Alma, Eleonora and Annunziata, Salvatore and Sica, Simona and Leccisotti, Lucia and Hohaus, Stefan},
title = {Baseline Tumor Burden Assessed With AI‐Guided PET/CT Total Metabolic Tumor Volume (TMTV) and LDH Levels Predict Efficacy of CAR‐T in Aggressive B‐Cell Lymphoma},
journal = {Hematological Oncology},
year = {2025},
volume = {43},
number = {1},
doi = {10.1002/hon.70029}
}
EUVIMED